CIK: 0002088557
Total reported value
$712.2M
Reporting period: 2026-03-31 · Number of holdings: 31
Defilade Capital Management, L.P. disclosed 31 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $712.2M and a quarterly turnover rate of 98.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
Defilade Capital Management, L.P.'s disclosed holdings carry a Herfindahl concentration index of 0.041 — mathematically equivalent to about 24 equally-sized positions, close to its 31 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.54), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 70% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim PFE
-33.6% -$35.5M
Add BDX
+243.8% $28.1M
Add INSM
+289.8% $23.2M
Add HSIC
+94.8% $21.8M
Add DXCM
+120.0% $17.6M
Trim PACS
-47.3% -$18.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZBH | Zimmer Biomet Holdings INC | Stock-Healthcare | 7.35% | +7.35% | NEW | |
| 2 | HSIC | Henry Schein INC | Stock-Healthcare | 6.46% | +3.18% | +94.75% | |
| 3 | BDX | Becton Dickinson And Co | Stock-Healthcare | 6.16% | +4.02% | +243.82% | |
| 4 | PTCT | Ptc Therapeutics INC | Stock-Healthcare | 5.77% | +5.77% | NEW | |
| 5 | DXCM | Dexcom INC | Stock-Healthcare | 4.75% | +2.55% | +120.01% | |
| 6 | ICUI | Icu Medical INC | Stock-Other | 4.61% | -1.98% | -25.37% | |
| 7 | INSM | Insmed INC | Stock-Healthcare | 4.48% | +3.30% | +289.82% | |
| 8 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 4.38% | +0.87% | +48.22% | |
| 9 | RVMD | Revolution Medicines INC | Stock-Healthcare | 4.31% | +0.39% | -13.06% | |
| 10 | GMED | Globus Medical INC - A | Stock-Healthcare | 4.29% | +1.13% | +32.61% | |
| 11 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 3.88% | +3.88% | NEW | |
| 12 | DNLI | Denali Therapeutics INC | Stock-Other | 3.67% | +2.20% | +107.09% | |
| 13 | PACS | Pacs Group INC | Stock-Other | 3.60% | -2.36% | -47.26% | |
| 14 | OLMA | Olema Pharmaceuticals INC | Stock-Other | 3.15% | -1.03% | +21.86% | |
| 15 | ELAN | Elanco Animal Health INC | Stock-Healthcare | 3.13% | +1.90% | +132.04% | |
| 16 | PFE | Pfizer INC | Stock-Healthcare | 2.72% | -4.72% | -33.55% | |
| 17 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.67% | -1.98% | -35.22% | |
| 18 | LNTH | Lantheus Holdings INC | Stock-Healthcare | 2.66% | +2.66% | NEW | |
| 19 | ITGR | Integer Holdings CORP | Stock-Healthcare | 2.63% | +2.63% | NEW | |
| 20 | BIIB | Biogen INC | Stock-Healthcare | 2.48% | -1.38% | -40.56% | |
| 21 | EVMN | Evommune INC | Stock-Other | 2.19% | +1.69% | +215.01% | |
| 22 | TNDM | Tandem Diabetes Care INC | Stock-Other | 2.05% | +2.05% | NEW | |
| 23 | COGT | Cogent Biosciences INC | Stock-Other | 1.91% | -0.83% | -37.99% | |
| 24 | NUVL | Nuvalent Inc-a | Stock-Other | 1.87% | -1.80% | -51.70% | |
| 25 | OCUL | Ocular Therapeutix INC | Stock-Other | 1.77% | +0.65% | +118.24% | |
| 26 | ASND | Ascendis Pharma A/S | Stock-Other | 1.67% | -0.81% | -39.44% | |
| 27 | ALGN | Align Technology INC | Stock-Healthcare | 1.62% | -1.09% | -47.42% | |
| 28 | ELDN | Eledon Pharmaceuticals INC | Stock-Other | 1.54% | +0.87% | +8.32% | |
| 29 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 1.50% | +1.50% | NEW | |
| 30 | BHVN | Biohaven Ltd. | Stock-Other | 0.38% | +0.38% | NEW | |
| 31 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.35% | +0.35% | NEW |
Performance for Q3 2026
+6.6%
Performance Last 4 Quarters
+3%
Based on 5 months of available history
Based on 67% of reported portfolio value with available pricing
Defilade Capital Management, L.P.'s most significant position changes for 2026-03-31: New buy: Zimmer Biomet Holdings INC (ZBH); Sold out: Abbvie INC (ABBV); Sold out: Novartis Ag-sponsored Adr (NVS); New buy: Ptc Therapeutics INC (PTCT); Sold out: STERIS plc (STE).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson And Co | +4% | +243.82% | Add |
| 2 | INSM | Insmed INC | +3.3% | +289.82% | Add |
| 3 | HSIC | Henry Schein INC | +3.2% | +94.75% | Add |
| 4 | DXCM | Dexcom INC | +2.6% | +120.01% | Add |
| 5 | DNLI | Denali Therapeutics INC | +2.2% | +107.09% | Add |
| 6 | ELAN | Elanco Animal Health INC | +1.9% | +132.04% | Add |
| 7 | EVMN | Evommune INC | +1.7% | +215.01% | Add |
| 8 | GMED | Globus Medical INC - A | +1.1% | +32.61% | Add |
| 9 | ELDN | Eledon Pharmaceuticals INC | +0.9% | +8.32% | Add |
| 10 | ISRG | Intuitive Surgical INC | +0.9% | +48.22% | Add |
| 11 | OCUL | Ocular Therapeutix INC | +0.7% | +118.24% | Add |
| 12 | RVMD | Revolution Medicines INC | +0.4% | -13.06% | Trim |
| 13 | ASND | Ascendis Pharma A/S | -0.8% | -39.44% | Trim |
| 14 | COGT | Cogent Biosciences INC | -0.8% | -37.99% | Trim |
| 15 | OLMA | Olema Pharmaceuticals INC | -1% | +21.86% | Add |
| 16 | ALGN | Align Technology INC | -1.1% | -47.42% | Trim |
| 17 | BIIB | Biogen INC | -1.4% | -40.56% | Trim |
| 18 | NUVL | Nuvalent Inc-a | -1.8% | -51.70% | Trim |
| 19 | ICUI | Icu Medical INC | -2% | -25.37% | Trim |
| 20 | LLY | Eli Lilly & Co | -2% | -35.22% | Trim |
| 21 | PACS | Pacs Group INC | -2.4% | -47.26% | Trim |
| 22 | PFE | Pfizer INC | -4.7% | -33.55% | Trim |
| 23 | ZBH | Zimmer Biomet Holdings INC | — | NEW | New buy |
| 24 | ABBV | Abbvie INC | — | EXIT | Sold out |
| 25 | NVS | Novartis Ag-sponsored Adr | — | EXIT | Sold out |
| 26 | PTCT | Ptc Therapeutics INC | — | NEW | New buy |
| 27 | STE | STERIS plc | — | EXIT | Sold out |
| 28 | NBIX | Neurocrine Biosciences INC | — | NEW | New buy |
| 29 | XNCR | Xencor INC | — | EXIT | Sold out |
| 30 | LNTH | Lantheus Holdings INC | — | NEW | New buy |
| 31 | ITGR | Integer Holdings CORP | — | NEW | New buy |
| 32 | ATRC | Atricure INC | — | EXIT | Sold out |
| 33 | LIVN | LivaNova PLC | — | EXIT | Sold out |
| 34 | TNDM | Tandem Diabetes Care INC | — | NEW | New buy |
| 35 | ATEC | Alphatec Holdings INC | — | EXIT | Sold out |
| 36 | ORIC | Oric Pharmaceuticals INC | — | NEW | New buy |
| 37 | GKOS | Glaukos CORP | — | EXIT | Sold out |
| 38 | RXST | Rxsight INC | — | EXIT | Sold out |
| 39 | TFX | Teleflex INC | — | EXIT | Sold out |
| 40 | CNMD | Conmed CORP | — | EXIT | Sold out |
| 41 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 42 | MREO | Mereo Biopharma Group Pl-adr | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002109121
Total reported value
$712.2M
177 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001803291
Total reported value
$712.1M
110 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001677501
Total reported value
$711.9M
520 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000884535
Total reported value
$730.9M
67 stks
2019-03-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Dexcom INC
CIK 0000896159
Total reported value
$29.9M
3 stks
2022-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Ptc Therapeutics INC
CIK 0000922940
Total reported value
$1.3B
36 stks
2026-03-31
1 of the top 5 holdings overlap, including Henry Schein INC